Dyno Therapeutics is using DNA technologies and machine learning to develop novel gene therapy vectors. AAVs are widely used vectors for gene therapies, but they still come with limitations, such as targeting and payload size. Dyno’s approach focuses on enhancing AAV gene therapy vectors through diversifying the capsid protein. This is done using their CapsidMapTM platform involving AI-guided engineered protein libraries.
Through developing a synthetic AAV capsid sequence space, Dyno will navigate the landscape to discover enhanced gene therapy vectors which can then be licensed for therapeutic use.